JP2016501523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501523A5 JP2016501523A5 JP2015545446A JP2015545446A JP2016501523A5 JP 2016501523 A5 JP2016501523 A5 JP 2016501523A5 JP 2015545446 A JP2015545446 A JP 2015545446A JP 2015545446 A JP2015545446 A JP 2015545446A JP 2016501523 A5 JP2016501523 A5 JP 2016501523A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- percentile
- individual
- telomere length
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732263P | 2012-11-30 | 2012-11-30 | |
| US61/732,263 | 2012-11-30 | ||
| US201361780851P | 2013-03-13 | 2013-03-13 | |
| US61/780,851 | 2013-03-13 | ||
| US13/802,035 US9200327B2 (en) | 2012-11-30 | 2013-03-13 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| US13/802,035 | 2013-03-13 | ||
| US201361798478P | 2013-03-15 | 2013-03-15 | |
| US61/798,478 | 2013-03-15 | ||
| US201361809228P | 2013-04-05 | 2013-04-05 | |
| US61/809,228 | 2013-04-05 | ||
| PCT/US2013/072302 WO2014085632A1 (en) | 2012-11-30 | 2013-11-27 | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018022923A Division JP2018099127A (ja) | 2012-11-30 | 2018-02-13 | テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501523A JP2016501523A (ja) | 2016-01-21 |
| JP2016501523A5 true JP2016501523A5 (https=) | 2017-01-19 |
| JP6359028B2 JP6359028B2 (ja) | 2018-07-18 |
Family
ID=50828470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545446A Active JP6359028B2 (ja) | 2012-11-30 | 2013-11-27 | テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー |
| JP2018022923A Pending JP2018099127A (ja) | 2012-11-30 | 2018-02-13 | テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018022923A Pending JP2018099127A (ja) | 2012-11-30 | 2018-02-13 | テロメラーゼ阻害剤を用いて細胞増殖性障害を処置するための診断マーカー |
Country Status (24)
| Country | Link |
|---|---|
| EP (4) | EP3882355B1 (https=) |
| JP (2) | JP6359028B2 (https=) |
| KR (3) | KR102174763B1 (https=) |
| CN (2) | CN104937110A (https=) |
| AU (4) | AU2013352105B2 (https=) |
| BR (1) | BR112015012507B1 (https=) |
| CA (1) | CA2892445C (https=) |
| CY (1) | CY1124140T1 (https=) |
| DK (2) | DK3495495T3 (https=) |
| ES (3) | ES2865446T3 (https=) |
| HR (2) | HRP20181991T1 (https=) |
| HU (1) | HUE054053T2 (https=) |
| IL (3) | IL282112B (https=) |
| LT (2) | LT2925889T (https=) |
| MX (1) | MX362094B (https=) |
| NZ (2) | NZ708654A (https=) |
| PL (2) | PL3495495T3 (https=) |
| PT (2) | PT3495495T (https=) |
| RS (1) | RS61513B1 (https=) |
| SG (1) | SG11201504209YA (https=) |
| SI (2) | SI3495495T1 (https=) |
| SM (1) | SMT202100142T1 (https=) |
| WO (1) | WO2014085632A1 (https=) |
| ZA (2) | ZA201900759B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3029154T (lt) | 2008-10-17 | 2017-12-27 | Geron Corporation | Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| JPWO2018207952A1 (ja) * | 2017-05-12 | 2020-04-16 | 国立大学法人九州大学 | 発毛及び／又は育毛用組成物 |
| KR102867725B1 (ko) | 2017-07-28 | 2025-10-13 | 제론 코포레이션 | 골수형성이상 증후군의 치료 방법 |
| US20200063214A1 (en) * | 2018-07-31 | 2020-02-27 | Geron Corporation | Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor |
| GB201818792D0 (en) * | 2018-11-19 | 2019-01-02 | Telonostix Ltd | Compounds for telomere length-related treatment of cancer |
| UA130012C2 (uk) | 2018-11-29 | 2025-10-15 | Джерон Корпорейшн | Спосіб лікування мієлодиспластичного синдрому |
| EP3674418A1 (en) * | 2018-12-26 | 2020-07-01 | Life Length S.L. | Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases |
| CN114306602B (zh) * | 2020-09-28 | 2024-06-11 | 中国科学院上海营养与健康研究所 | 靶向tert在调节皮肤及毛发色素中的应用 |
| CN115463122B (zh) * | 2022-08-16 | 2025-03-25 | 吕梁学院 | 一种增强盐霉素抗癌活性的方法及应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| AU733610B2 (en) | 1996-12-20 | 2001-05-17 | Geron Corporation | Methods for detecting and inhibiting the RNA component of telomerase |
| JPH11276182A (ja) * | 1997-12-26 | 1999-10-12 | Chugai Pharmaceut Co Ltd | 逆転写酵素モチーフを有する新規遺伝子 |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| CA2474468C (en) | 2002-01-31 | 2014-03-25 | University Of Utah | Amplifying repetitive nucleic acid sequences |
| US20040234961A1 (en) * | 2002-04-22 | 2004-11-25 | Fordyce Colleen A. | Telomere length determination and applications |
| WO2004068110A2 (en) | 2003-01-24 | 2004-08-12 | University Of Utah | Methods of predicting mortality risk by determining telomere length |
| CN100393209C (zh) | 2003-09-09 | 2008-06-11 | 杰龙公司 | 用于端粒酶抑制的改性寡核苷酸 |
| ME02933B (me) | 2004-07-02 | 2018-04-20 | Geron Corp | Sinteza zaštićenih 3'-amino nukleozionih monomera |
| CA2602562C (en) * | 2005-03-25 | 2015-07-07 | Alt Solutions, Inc. | Modulation of telomere length in telomerase positive cells and cancer therapy |
| EP1876893B1 (en) * | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| LT3029154T (lt) * | 2008-10-17 | 2017-12-27 | Geron Corporation | Paciento jautrumo telomerazės slopinimo terapijai nustatymo būdas |
| US9689028B2 (en) | 2008-12-22 | 2017-06-27 | University Of Utah Foundation | Monochrome multiplex quantitative PCR |
| US20110207128A1 (en) | 2010-02-16 | 2011-08-25 | Cawthon Richard M | Methods and kits for determining biological age and longevity based on gene expression profiles |
| ES2656958T3 (es) * | 2011-03-28 | 2018-03-01 | Geron Corporation | Medición de la longitud de telómeros en muestras fijadas en formalina, embebidas en parafina (FFPE) por PCR cuantitativa |
-
2013
- 2013-11-27 CA CA2892445A patent/CA2892445C/en active Active
- 2013-11-27 EP EP20214086.9A patent/EP3882355B1/en active Active
- 2013-11-27 HU HUE18192236A patent/HUE054053T2/hu unknown
- 2013-11-27 PT PT181922360T patent/PT3495495T/pt unknown
- 2013-11-27 HR HRP20181991TT patent/HRP20181991T1/hr unknown
- 2013-11-27 CN CN201380070816.5A patent/CN104937110A/zh active Pending
- 2013-11-27 ES ES18192236T patent/ES2865446T3/es active Active
- 2013-11-27 NZ NZ708654A patent/NZ708654A/en unknown
- 2013-11-27 DK DK18192236.0T patent/DK3495495T3/da active
- 2013-11-27 ES ES13858528T patent/ES2703914T3/es active Active
- 2013-11-27 SG SG11201504209YA patent/SG11201504209YA/en unknown
- 2013-11-27 RS RS20210254A patent/RS61513B1/sr unknown
- 2013-11-27 NZ NZ748624A patent/NZ748624A/en unknown
- 2013-11-27 PL PL18192236T patent/PL3495495T3/pl unknown
- 2013-11-27 PL PL13858528T patent/PL2925889T3/pl unknown
- 2013-11-27 LT LTEP13858528.6T patent/LT2925889T/lt unknown
- 2013-11-27 WO PCT/US2013/072302 patent/WO2014085632A1/en not_active Ceased
- 2013-11-27 KR KR1020157017235A patent/KR102174763B1/ko active Active
- 2013-11-27 KR KR1020217027659A patent/KR20210112394A/ko not_active Ceased
- 2013-11-27 DK DK13858528.6T patent/DK2925889T3/da active
- 2013-11-27 EP EP24188387.5A patent/EP4497441A2/en not_active Withdrawn
- 2013-11-27 LT LTEP18192236.0T patent/LT3495495T/lt unknown
- 2013-11-27 KR KR1020207031441A patent/KR102348240B1/ko active Active
- 2013-11-27 CN CN201911349502.4A patent/CN111494629A/zh active Pending
- 2013-11-27 SM SM20210142T patent/SMT202100142T1/it unknown
- 2013-11-27 PT PT13858528T patent/PT2925889T/pt unknown
- 2013-11-27 MX MX2015006538A patent/MX362094B/es active IP Right Grant
- 2013-11-27 EP EP13858528.6A patent/EP2925889B1/en active Active
- 2013-11-27 EP EP18192236.0A patent/EP3495495B1/en active Active
- 2013-11-27 SI SI201331864T patent/SI3495495T1/sl unknown
- 2013-11-27 IL IL282112A patent/IL282112B/en unknown
- 2013-11-27 JP JP2015545446A patent/JP6359028B2/ja active Active
- 2013-11-27 SI SI201331271T patent/SI2925889T1/sl unknown
- 2013-11-27 AU AU2013352105A patent/AU2013352105B2/en active Active
- 2013-11-27 BR BR112015012507-7A patent/BR112015012507B1/pt active IP Right Grant
- 2013-11-27 ES ES20214086T patent/ES2972330T3/es active Active
-
2015
- 2015-05-27 IL IL239035A patent/IL239035B/en active IP Right Grant
-
2018
- 2018-02-13 JP JP2018022923A patent/JP2018099127A/ja active Pending
-
2019
- 2019-02-06 ZA ZA2019/00759A patent/ZA201900759B/en unknown
- 2019-11-13 IL IL270636A patent/IL270636B/en active IP Right Grant
- 2019-12-18 AU AU2019283840A patent/AU2019283840A1/en not_active Abandoned
-
2021
- 2021-02-26 ZA ZA2021/01317A patent/ZA202101317B/en unknown
- 2021-03-17 HR HRP20210451TT patent/HRP20210451T1/hr unknown
- 2021-03-23 CY CY20211100256T patent/CY1124140T1/el unknown
-
2022
- 2022-04-28 AU AU2022202808A patent/AU2022202808B2/en active Active
-
2025
- 2025-02-25 AU AU2025201333A patent/AU2025201333B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501523A5 (https=) | ||
| Xie et al. | MicroRNAs as regulators, biomarkers and therapeutic targets in the drug resistance of colorectal cancer | |
| JOP20210207A1 (ar) | مركبات ترابطية مستهدفة | |
| JOP20210231A1 (ar) | مركبات ترابطية مستهدفة كمركبات علاجية | |
| WO2010141511A3 (en) | Polynucleotides for multivalent rna interference, compositions and methods of use thereof | |
| ES2686549T3 (es) | Método para seleccionar una triterapia personalizada para el tratamiento del cáncer | |
| HRP20210451T1 (hr) | Dijagnostički markeri za liječenje staničnih poremećaja proliferacije inhibitorima telomeraza | |
| WO2016106404A3 (en) | Methods and compositions for treating malignant tumors associated with kras mutation | |
| JP2016074736A5 (https=) | ||
| JP2018502956A5 (https=) | ||
| JP2018508469A5 (https=) | ||
| UA118014C2 (uk) | Спосіб модифікації днк-мішені | |
| WO2016094845A3 (en) | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides | |
| JP2017513908A5 (https=) | ||
| JP2019527563A5 (https=) | ||
| JP2011515357A5 (https=) | ||
| JP2022516054A5 (https=) | ||
| CY1123599T1 (el) | Συνθεσεις και μεθοδοι για τη διορθωση ζωνιαιας μυικης δυστροφιας τυπου 2c με τη χρησιμοποιηση παραλειψης εξονιων | |
| RU2013119459A (ru) | Комплекс ipp в качестве маркера лечения эрлотинибом | |
| Zhang et al. | Different expression of alternative lengthening of telomere (ALT)-associated proteins/mRNAs in osteosarcoma cell lines | |
| Nakatani et al. | A dimeric form of N-methoxycarbonyl-2-amino-1, 8-naphthyridine bound to the A–A mismatch in the CAG/CAG base triad in dsRNA | |
| JP2021500026A5 (https=) | ||
| CN106906213A (zh) | 一种修饰的siRNA及其用途 | |
| Springfeld et al. | New implications from long-term outcomes of perioperative therapy in resectable pancreatic cancer: Clinical Studies | |
| Huse et al. | Yin and yang: cancer-implicated miRNAs that have it both ways |